How big is Janux Therapeutics, Inc.?

As of Jun 18, Janux Therapeutics, Inc. has a market capitalization of 1,365.77 million, with net sales of 9.34 million and a net profit of -77.75 million over the latest four quarters. The company reported shareholder's funds of 1,022.78 million and total assets of 1,061.52 million as of Dec 24.

Market Cap: As of Jun 18, Janux Therapeutics, Inc. has a market capitalization of 1,365.77 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Janux Therapeutics, Inc. reported net sales of 9.34 million and a net profit of -77.75 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,022.78 million and total assets of 1,061.52 million.

What does Janux Therapeutics, Inc. do?

Janux Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $24 million and a market cap of approximately $1.37 billion. The company has no dividend yield and negative return on equity.

Overview: <BR>Janux Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -24 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 1,365.77 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -7.68% <BR>Price to Book: 1.35<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Janux Therapeutics, Inc.?

Is Janux Therapeutics, Inc. overvalued or undervalued?

As of August 7, 2025, Janux Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade, with negative earnings metrics and a year-to-date return of -54.43%, significantly underperforming compared to the S&P 500's 12.22% return.

As of 7 August 2025, the valuation grade for Janux Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is considered overvalued given its current metrics, particularly with a Price to Book Value of 1.54, an EV to EBIT of -4.84, and an EV to EBITDA of -4.93, which reflect negative earnings performance. <BR><BR>In comparison to its peer Avidity Biosciences, Inc., which has a P/E ratio of -13.5642 and an EV to EBITDA of -9.6438, Janux appears to be in a weaker position. The company's returns have also lagged significantly behind the S&P 500, with a year-to-date return of -54.43% compared to the index's 12.22%, reinforcing the perception of overvaluation.

Is Janux Therapeutics, Inc. technically bullish or bearish?

As of September 26, 2025, Janux Therapeutics, Inc. has shifted to a mildly bearish trend, with mixed indicators showing underperformance against the S&P 500, including a year-to-date return of -56.61% compared to the S&P's 12.96%.

As of 26 September 2025, the technical trend for Janux Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The moving averages indicate a bearish trend on the daily. Additionally, the Dow Theory and Bollinger Bands are both mildly bearish on the monthly timeframe. <BR><BR>In terms of performance, Janux has underperformed the S&P 500 across multiple periods, with a year-to-date return of -56.61% compared to the S&P 500's 12.96%, and a one-year return of -50.17% versus 15.64% for the benchmark.